Open AccessLong‐lasting response to third‐line crizotinib treatment in a patient with non‐small cell lung cancer with brain metastases and poor performance status
Author(s) -
Li Delan,
Chen Xinru,
Ma Shuxiang,
Chen Likun
Publication year - 2016
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12383
Subject(s) - crizotinib , anaplastic lymphoma kinase , medicine , alk inhibitor , lung cancer , oncology , brain metastasis , chemotherapy , cancer research , cancer , metastasis , malignant pleural effusion
Identification of the anaplastic lymphoma kinase ( ALK ) gene has refined the classification of non‐small cell lung cancer ( NSCLC ) and promoted research on molecularly targeted drugs such as crizotinib, an ALK inhibitor with good efficacy, in ALK ‐rearranged NSCLC . At present, few studies have reported the efficacy of crizotinib in patients with ALK ‐rearranged NSCLC with brain metastases. In a patient with NSCLC harboring ALK ‐rearrangement who had brain metastases and poor performance status ( PS ), we obtained a durable response with crizotinib administered following multi‐line chemotherapy regimens.